Matrine promotes colorectal cancer apoptosis by downregulating shank-associated RH domain interactor expression

Table 1 Clinicalpathological charateristics of colorectal cancer according to Shank-associated RH domain interactor expression, n (%)

Variables	Total (n = 93)	Low (n = 50)	High (n = 43)	P value
Sex, male	49 (52.7)	28 (56)	21 (48.8)	0.49
Age, years	67.5 ± 10.9	67.4 ± 10.6	67.7 ± 11.4	0.89
Location				0.38
Left	75 (80.6)	42 (84)	33 (76.7)
Right	18 (19.4)	8 (16)	10 (23.3)
Gross type				0.03
Fungating	32 (34.4)	21 (42)	11 (25.6)
Ulceroinfiltrative	54 (58.1)	23 (46)	31 (72.1)
Ulcerofungating	7 (7.5)	6 (12)	1 (2.3)
Differentiation				0.443
Poor	10 (11.1)	3 (10.3)	4 (12.5)
Moderate	70 (77.8)	21 (72.4)	26 (81.2)
Well	10 (11.1)	5 (17.2)	2 (6.2)
Tumor size, ≥ 5 cm	48 (51.6)	24 (48)	24 (55.8)	0.45
Histopathologic type				0.76
AC	79 (84.9)	43 (86)	36 (83.7)
MAC	14 (15.1)	7 (14)	7 (16.3)
Venous invasion	21 (22.6)	10 (20)	11 (25.6)	0.52
Perineural invasion	48 (51.6)	24 (48)	24 (55.8)	0.45
MSI	7 (7.5)	3 (6)	4 (9.3)	0.70
T stage				0.02
1	4 (4.3)	4 (8)	0 (0)
2	17 (18.3)	13 (26)	4 (9.3)
3	60 (64.5)	29 (58)	31 (72.1)
4	12 (12.9)	4 (8)	8 (18.6)
N stage				0.02
0	63 (67.7)	40 (80)	23 (53.5)
1	18 (19.4)	7 (14)	11 (25.6)
2	12 (12.9)	3 (6)	9 (20.9)
M stage				0.09
0	87 (93.5)	49 (98)	38 (88.4)
1	6 (6.5)	1 (2)	5 (11.6)
TNM stage				0.01
Ⅰ	20 (21.5)	16 (32)	4 (9.3)
Ⅱ	41 (44.1)	22 (44)	19 (44.2)
Ⅲ	26 (28.0)	11 (22)	15 (34.9)
Ⅳ	6 (6.5)	1 (2)	5 (11.6)
CA125, ng/mL	9.0 (7.0, 14.5)	9.0 (7.0, 14.5)	9.0 (7.1, 13.7)	0.96
CA199, U/mL	14.1 (9.2, 24.0)	14.5 (8.0, 23.0)	13.6 (10.0, 26.0)	0.97
CA724, U/mL	1.7 (1.5, 4.7)	1.9 (1.5, 4.9)	1.6 (1.5, 2.8)	0.61
CEA, ng/mL	4.8 (2.5, 11.1)	5.5 (2.6, 11.5)	3.5 (2.5, 8.8)	0.26
CA153, U/mL	8.1 (6.0, 12.4)	7.2 (5.3, 10.6)	9.2 (6.9, 13.3)	0.04

Two groups were divided the mean of the H-score. AC: Adenocarcinoma; MAC: Mucinous adenocarcinoma; MSI: Microsatellite instability; CEA Carcinoembryonic antigen; CA199: Carbohydrate antigen 19-9; CA724: Carbohydrate antigen 724; TNM: Tumor-node-metastasis.